Related to EC Follows FDA and Approves Lilly’s Erectile Dysfunction Drug for BPH

• EMA Green-Lights Shire’s Manufacturing Site in Lexington, MA, for Gaucher Therapy
  
• EC Approves Three-Year Treatment Label Update for Novartis’ Glivec
  
• EC Grants CE Mark for Trinity’s Point-of-Care Test for Giardiasis
  
• Abbott Achieves CE Mark for PLEX-ID Microbial Identification Technology, Assays
  
• EC Approves Novartis’ Cushing Disease Therapy Signifor
  
• EC Sanctions Pharmaxis’ Bronchitol as Add-On Therapy for Cystic Fibrosis
  
• Genzyme Gets FDA, EMA Approvals for Production Plant in Waterford, Ireland
  
• EC Conditionally Approves Cell Therapeutics’ Pixantrone for Non-Hodgkin Lymphoma
  
• Curetis Wins CE Mark for POC Diagnostic Platform, Pneumonia Test Cartridge
  
• IntelligentMDx Wins CE Mark for Group B Strep Assay on Abbott m2000 Instrument
  
• BioDelivery Earns $2.5M from Meda on Pricing Approval of Breakyl in First EU Country
  
• First Gene Therapy One Step Away from European Sanction
  
• CE Mark for Rapid Acute Kidney Injury Test
  
• EC Conditionally Sanctions Lymphoma Treatment
  
• FDA Approves Novartis' Flucelvax
  
• Exelixis Scores First FDA Approval for Thyroid Cancer Drug
  
• EC Approves Lilly, Amylin, and Alkermes’ Once-Weekly Type 2 Diabetes Drug Bydureon
  
• BI and Lilly’s Linagliptin Now Approved to Treat Type 2 Diabetes in Europe
  
• Amylin, Lilly Confirm EU Approval of Byetta as Adjunct to Insulin for Type 2 Diabetes
  
• FDA Clears Lilly’s Cialis for Treating Symptoms of BPH in Men with or without Erectile Dysfunction